8-K - aTyr Pharma, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

aTyr Pharma announced fourth quarter and full year 2025 results, reporting a net loss of $74.1 million for the year ended December 31, 2025. The company ended 2025 with $80.9 million in cash and investments and scheduled a Type C meeting with the FDA for mid-April 2026 to review the Phase 3 EFZO-FIT study results.

Key Takeaways

1Phase 3 EFZO-FIT study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.

2Company scheduled to meet with the FDA in mid-April 2026 to review Phase 3 results and determine the path forward for efzofitimod in pulmonary sarcoidosis.

3Phase 2 EFZO-CONNECT study in SSc-ILD is on track to complete enrollment in the first half of 2026.

4Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments.

5Net loss for the year ended December 31, 2025 was $74.1 million, or $0.80 per share, compared to $64.0 million, or $0.86 per share, for the prior year.

Current Report Details

Event Type

Financial Results

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

, including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as

Financial Results

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated March 5, 2026 104 Cover Page Interactive Data File (embedded w

Exhibits Only

Results of Operations

Fourth Quarter and Full Year 2025

Metric	Value	Prior Period
Total revenues	$0.19	$0.24
Research and development expenses	$60.22	$54.37
General and administrative expenses	$17.60	$13.78
Net loss	$74.12	$64.02
Net loss per share	$-0.80	$-0.86

Exhibits (2)

8-K

99.1

EX-99.1